InvestorsHub Logo
Followers 5
Posts 475
Boards Moderated 0
Alias Born 09/27/2012

Re: None

Monday, 12/10/2012 4:23:00 PM

Monday, December 10, 2012 4:23:00 PM

Post# of 346054
It appears they downgraded "Major Discrepancies" to mere discrepancies...

Upcoming clinical milestones for the program include key median overall survival endpoints in pancreatic and front-line non-small cell lung cancer and final results from our second-line non-small cell lung cancer study in which we discovered discrepancies and have subsequently been intensely reviewing. The goal of this review is to be able to generate a final data set that we believe could be used to support advancing the program into a pivotal trial.

.

...just an observation on the tenor of the language vs the 9/24 PR.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News